dc.contributor.author
Darbà, Josep
dc.contributor.author
Marsà, Alícia
dc.date.issued
2021-06-10T20:45:48Z
dc.date.issued
2022-05-04T05:10:21Z
dc.date.issued
2021-05-04
dc.date.issued
2021-06-10T20:45:49Z
dc.identifier
https://hdl.handle.net/2445/178242
dc.description.abstract
Intrahepatic cholangiocarcinomas (iCCA) are aggressive tumors, often diagnosed in advanced stages and with limited curative treatment options. Their incidence has raised in the past years, increasing their associated economic burden. This study aimed to measure hospital incidence and mortality of iCCA and to evaluate direct medical costs.
dc.format
application/pdf
dc.publisher
Informa Healthcare
dc.relation
Versió postprint del document publicat a: https://doi.org/10.1080/14737167.2021.1842201
dc.relation
Expert Review of Pharmacoeconomics & Outcomes Research, 2021, vol. 21, núm. 3, p. 425-431
dc.relation
https://doi.org/10.1080/14737167.2021.1842201
dc.rights
(c) Informa Healthcare, 2021
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Economia)
dc.subject
Cost de l'assistència sanitària
dc.subject
Gestió hospitalària
dc.subject
Malalties del fetge
dc.subject
Cost of medical care
dc.subject
Hospital administration
dc.subject
Liver diseases
dc.title
Analysis of hospital incidence and direct medical costs of intrahepatic cholangiocarcinoma in Spain (2000-2018)
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/acceptedVersion
